Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 48

Results For "BSE"

973 News Found

USFDA inspects Shilpa Medicare’s bio-analytical laboratory in Hyderabad
Drug Approval | March 02, 2024

USFDA inspects Shilpa Medicare’s bio-analytical laboratory in Hyderabad

This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently


Cipla incorporates JV company in USA
News | March 02, 2024

Cipla incorporates JV company in USA

Cipla completes transfer of Generics Business Undertaking


Briefs: Eugia Pharma Specialities and Eugia SEZ
News | March 01, 2024

Briefs: Eugia Pharma Specialities and Eugia SEZ

Eugia Pharma Specialities restarts production at terminally sterilized product lines


ABHA based Scan and Share Service facilitates 2 Crore instant OPD registrations nationwide
Digitisation | February 28, 2024

ABHA based Scan and Share Service facilitates 2 Crore instant OPD registrations nationwide

Patients visiting OPD sections of hospitals use their Ayushman Bharat Health Account (ABHA) to get instant tokens to save time spent in registration queues


Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides
News | February 20, 2024

Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides

IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China


GSK completes acquisition of Aiolos Bio
News | February 19, 2024

GSK completes acquisition of Aiolos Bio

The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody


Marksans Q3 FY24 revenue up 22% at Rs 586 Cr
News | February 16, 2024

Marksans Q3 FY24 revenue up 22% at Rs 586 Cr

Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%


Qure.ai adds new FDA breakthrough device status for qSpot-TB
Digitisation | February 09, 2024

Qure.ai adds new FDA breakthrough device status for qSpot-TB

4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months


AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study
Clinical Trials | January 31, 2024

AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study

About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation


Shilpa Medicare updates on Europe GMP inspection at Unit 4, Jadcherla, Telangana
Drug Approval | January 28, 2024

Shilpa Medicare updates on Europe GMP inspection at Unit 4, Jadcherla, Telangana

The company intends to respond to the two minor observations within the stipulated time